AI Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics
Development and Validation of Artificial Intelligence Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics
1 other identifier
observational
30
0 countries
N/A
Brief Summary
This observational study aims to recruit up to thirty T1DM patients from a diabetic outpatient clinic at the University Hospital Coventry and Warwickshire for a two-phase study. The first phase involves attending an inpatient protocol for up to thirty-six hours in a calorimetry room at the Human Metabolism Research Unit under controlled conditions, followed by a phase of free-living, for up to three days, in which participants will go about their normal daily activities without restriction. Throughout the study, the participants will wear commercially available wearable sensors to measure and record physiological signals (e.g., electrocardiogram and continuous glucose monitor). Data collected will be used to develop and validate an AI model using state-of-the-art deep-learning methods for the purpose of non-invasive glycaemic event detection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2022
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2022
CompletedFirst Posted
Study publicly available on registry
July 15, 2022
CompletedStudy Start
First participant enrolled
September 30, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
ExpectedJuly 15, 2022
July 1, 2022
3.6 years
June 24, 2022
July 12, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Interstitial Glucose
As measured by a continuous glucose monitor \[NOTE\] Observational study thus a key measurement not a true outcome measure.
For the duration of the study, up to 5 days
Secondary Outcomes (4)
ECG -Interval across different fiducial points
For the duration of the study, up to 5 days
ECG - Slope across different fiducial points
For the duration of the study, up to 5 days
ECG - Indices of Heart Rate Variability
For the duration of the study, up to 5 days
Blood Pressure (Systolic and Diastolic)
For the duration of the study, up to 5 days
Study Arms (1)
Type1diabetes patients
Males and females diagnosed with T1D, aged over 18 years old who are currently under the care of the Warwickshire Institute for the Study of Diabetes, Endocrinolgy and Metabolism (WISDEM) at the University Hospitals Coventry and Warwickshire.
Eligibility Criteria
The population will be recruited from the Warwickshire Institute for the study of diabetes, Endocrinology and Metabolism, at the University Hospitals Coventry and Warwickshire. WISDEM is a flagship partnership between the hospitals and the University of Warwick Medical School created to tackle diabetes and related metabolic conditions.
You may qualify if:
- The study will be open to all individuals living independently, over 18 years without acute illness or ongoing clinical investigation, or volunteers with a stable medical condition may be included. Volunteers with an ongoing medical condition will only be included after detailed consultation with our clinical and dietetics members of the team; however, it is imperative that volunteers are able to provide written informed consent.
You may not qualify if:
- Children (under 18 yrs)
- Any adult who lacks decisional capacity
- Claustrophobia, isolophobia, recent abnormal exercise, radiation exposure within the preceding 24 hours of entering the whole-body calorimeter and feeling unwell in any way.
- Needle phobia
- Any medical/endocrine problem that could affect energy expenditure (e.g. thyroid problems, Cushing's syndrome)
- Chronic inflammatory disorders like rheumatoid arthritis, or long term use of steroids or other immunomodulators like cyclosporine, azathioprine.
- Beta blockers
- Currently actively losing weight
- Depression or any psychiatric illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Porumb M, Stranges S, Pescape A, Pecchia L. Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG. Sci Rep. 2020 Jan 13;10(1):170. doi: 10.1038/s41598-019-56927-5.
PMID: 31932608BACKGROUNDPorumb M, Griffen C, Hattersley J, Pecchia L. Nocturnal low glucose detection in healthy elderly from one-lead ECG using convolutional denoising autoencoders. Biomedical Signal Processing and Control. 2020;62:102054.
BACKGROUNDCisuelo O, Stokes K, Oronti IB, Haleem MS, Barber TM, Weickert MO, Pecchia L, Hattersley J. Development of an artificial intelligence system to identify hypoglycaemia via ECG in adults with type 1 diabetes: protocol for data collection under controlled and free-living conditions. BMJ Open. 2023 Apr 18;13(4):e067899. doi: 10.1136/bmjopen-2022-067899.
PMID: 37072364DERIVED
Biospecimen
Saliva samples for circadian biomarkers (cortisol, melatonin) Plasma for endocrine markers (insulin and glucose)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2022
First Posted
July 15, 2022
Study Start
September 30, 2022
Primary Completion
May 1, 2026
Study Completion (Estimated)
May 1, 2027
Last Updated
July 15, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share